Laura Huilaja Selected Research

Bullous Pemphigoid (Pemphigoid)

1/2023	Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
1/2022	Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
12/2021	GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid.
1/2020	Autoantibodies Against the Immunodominant Bullous Pemphigoid Epitopes Are Rare in Patients With Dermatitis Herpetiformis and Coeliac Disease.
5/2019	Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
1/2019	BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid.
1/2019	Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid".
12/2018	Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
1/2018	Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.
1/2017	Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Huilaja Research Topics

Disease

11	Bullous Pemphigoid (Pemphigoid) 01/2023 - 09/2014
5	Skin Diseases (Skin Disease) 01/2023 - 01/2013
5	Pruritus (Itching) 01/2023 - 01/2013
4	Pemphigoid Gestationis (Herpes Gestationis) 09/2015 - 04/2008
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2017
3	Blister (Bulla) 05/2015 - 01/2013
2	Dermatitis Herpetiformis (Disease, Duhring's) 10/2023 - 01/2020
2	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2023 - 01/2022
2	Type 2 Diabetes Mellitus (MODY) 01/2023 - 01/2022
2	Allergic Contact Dermatitis 09/2017 - 01/2014
1	Acne Vulgaris 07/2023
1	Tuberculosis (Tuberculoses) 01/2022
1	Neoplasms (Cancer) 11/2020
1	Breast Neoplasms (Breast Cancer) 11/2020
1	Colorectal Neoplasms (Colorectal Cancer) 11/2020
1	Epidermolysis Bullosa Simplex (Epidermolysis Bullosa Herpetiformis Dowling Meara) 01/2019
1	Multiple Sclerosis 01/2019
1	Epidermolysis Bullosa 01/2019
1	Basal Cell Carcinoma (Rodent Ulcer) 12/2018
1	Inflammation (Inflammations) 01/2018
1	Parkinson Disease (Parkinson's Disease) 12/2017
1	Nervous System Diseases (Neurological Disorders) 12/2017
1	Neuroinflammatory Diseases 12/2017
1	Hypersensitivity (Allergy) 09/2017
1	Skin Abnormalities 01/2017
1	Dementia (Dementias) 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Cognitive Dysfunction 01/2017
1	Exanthema (Rash) 09/2014
1	Osteoporosis 06/2014
1	Stress Fractures (Stress Fracture) 06/2014
1	Neurofibromatoses (Neurofibromatosis) 06/2014
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 06/2014
1	Pain (Aches) 01/2014
1	Acute Generalized Exanthematous Pustulosis 01/2014

Drug/Important Bio-Agent (IBA)

11	AutoantibodiesIBA 10/2023 - 04/2008
5	Collagen Type XVIIIBA 05/2015 - 04/2008
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2023 - 12/2018
4	Proteins (Proteins, Gene)FDA Link 11/2020 - 04/2008
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2023 - 05/2019
3	AutoantigensIBA 01/2022 - 04/2008
3	Immunoglobulin G (IgG)IBA 01/2019 - 01/2017
2	Insulin (Novolin)FDA Link 07/2023 - 12/2018
2	Glucose (Dextrose)FDA LinkGeneric 07/2023 - 01/2017
2	EpitopesIBA 01/2020 - 01/2019
2	AntigensIBA 12/2017 - 09/2014
2	AntibodiesIBA 12/2017 - 09/2015
1	TransglutaminasesIBA 10/2023
1	Protein Glutamine gamma Glutamyltransferase 2IBA 10/2023
1	Immunoglobulin A (IgA)IBA 10/2023
1	GliadinIBA 10/2023
1	Glutens (Glutelin)IBA 10/2023
1	Prednisolone (Predate)FDA LinkGeneric 03/2023
1	16S Ribosomal RNAIBA 01/2023
1	Collagen Type I (Type I Collagen)IBA 01/2023
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2023
1	CytokinesIBA 01/2023
1	gamma-Aminobutyric Acid (GABA)IBA 01/2023
1	guselkumabIBA 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2021
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2021
1	Keratin-5 (Keratin 5)IBA 01/2019
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 12/2018
1	C-Reactive ProteinIBA 01/2018
1	VildagliptinIBA 01/2018
1	AcidsIBA 09/2017
1	AllergensIBA 09/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2015
1	Diphosphonates (Bisphosphonates)IBA 06/2014
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 06/2014
1	Analgesics (Analgesic Drugs)IBA 01/2014
1	Irritants (Vesicants)IBA 01/2014
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 01/2014
1	Opioid Analgesics (Opioids)IBA 01/2014
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2014
1	ElementsIBA 04/2008

Therapy/Procedure

1	Therapeutics 06/2014